{"title":"REACTIVE OXYGEN-RELATED DISEASES: THERAPEUTIC TARGETS AND EMERGING CLINICAL INDICATIONS","authors":"Harald Schmidt","doi":"10.18143/JISANH_V3I3_1451","DOIUrl":null,"url":null,"abstract":"Numerous diseases and disease models have been suggested to be associated with oxidative stress; however very few if any have resulted in clinical application; some trials have been giant failures. Two innovations may provide a more successful and evidence-based way forward: the therapeutic move from focussing on ROS to their enzymatic sources and targets and the differentiation of physiological and pathological functions of these. Moreover a cluster of disease phenotypes within the so-called ‘diseasesome’ seems specifically linked to ROS- mediate pathologies.\nHere we present examples for such target validation within this cluster in diabetic end-organ damage and stroke, both linked by shared common redox mechanisms.\nThese therapeutic advances will be backed-up by precision diagnostics that enable early detection, patient stratification, detecting target engagement and therapeutic monitoring.","PeriodicalId":17323,"journal":{"name":"Journal of the International Society of Antioxidants in Nutrition & Health","volume":"392 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Society of Antioxidants in Nutrition & Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18143/JISANH_V3I3_1451","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Numerous diseases and disease models have been suggested to be associated with oxidative stress; however very few if any have resulted in clinical application; some trials have been giant failures. Two innovations may provide a more successful and evidence-based way forward: the therapeutic move from focussing on ROS to their enzymatic sources and targets and the differentiation of physiological and pathological functions of these. Moreover a cluster of disease phenotypes within the so-called ‘diseasesome’ seems specifically linked to ROS- mediate pathologies.
Here we present examples for such target validation within this cluster in diabetic end-organ damage and stroke, both linked by shared common redox mechanisms.
These therapeutic advances will be backed-up by precision diagnostics that enable early detection, patient stratification, detecting target engagement and therapeutic monitoring.